IDegLira for the real-world treatment of type 2 diabetes in Italy. Final results from the REX observational study.
Gian Poalo FadiniRaffaella BuzzettiDario PitoccoElena TortatoAlessia ScatenaOlga LamacchiaGiusi LastoriaLucia SimoniAgostino Consolinull nullPublished in: Diabetes, obesity & metabolism (2024)
Switching to IDegLira in a real-world clinical setting is a valid therapeutic option for patients with T2D with inadequate glycaemic control on basal or BB insulin regimen and/or need to simplify their insulin therapy, with specific reasons and therapeutic goals according to different T2D management trajectories.